Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose deutetrabenazine for moderate to severe tardive dyskinesia
2014-003135-19Phase 3Completed
- Sponsor
- Auspex Pharmaceuticals
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in tardive dyskinesia (TD) comparing Deutetrabenazine fixed-dose with Placebo (2 arms). Primary endpoint: Change in AIMS score from baseline to Week 12. Started Nov 2014; status: completed.
02
Drugs
deutetrabenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on 2014-003135-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003135-19.